Sagnik Nag, Amity University, Kolkata
Virologists have infected many miniature organs with SARS-CoV-2, to learn how the virus wreaks havoc and the means to prevent it. Chen, a stem-cell biologist at Weill Cornell Medicine in New York City, and her team had nurtured them from clumps of human cells, adding nutrients every occasional day as they thrived into 3D air sacs. A front-row impression of the virus rattling through the body could help researchers to spot ways to prevent it. Organoids aid to restore the gap between watching the infection in cell lines, which require the complexity of actual tissue, and in animal prototypes, which reflect human infection inadequately and are expensive.
These lung organoids matured until they reached the dimensions of a lentil. Then, the team picked them up and transported them just a couple of blocks away, to a laboratory authorized to figure with SARS-CoV-2, the virus liable for the COVID-19 pandemic. There, the organoids were drowned in virus and everyone was doused with one among 15,000 drugs. Most of the mini lungs died, but a couple of the drugs stemmed from the infection — representing a couple of possible treatments for COVID-19. These experiments, alongside research in animal prototypes, could assist to unravel a continual debate about what makes COVID-19 so lethal — the virus itself, or a hyperactive immune reaction. Ideally, researchers want to be ready to link organoids together. The screening is a component of a bigger project during which multiple labs are using different methods to review an equivalent compound, and comparing their results. Many research groups try to understand the potential of organoids for drug discovery.
Chen is one among many cell biologists who are driven by the pandemic to push the boundaries of organoid technology for studying infectious diseases. They need to learn which cells the virus targets, the speed of that attack, and the way the cells retaliate. Researchers have since shown that SARS-CoV-2 can infect several mini-organs, from the liver to kidneys to the brain — mimicking the multi-organ damage seen in some people with COVID-19. When researchers added a COVID-19 vaccine, a number of the tonsil organoids showed an immune response, observing killer T cells, also as antibodies that would assist the spike protein on the level of the virus.
The study helped to elucidate why some people with COVID-19 have digestive problems, including diarrhea and vomiting, and identified another possible route of transmission.
Although researchers have established the relevance of organoids for studying antiviral drugs, their work has not led to treatments. Organoid technology has improved further from the pandemic than the treatment of COVID-19 has supported organoids. Researchers also use some cancerous human cell lines but, almost like the Vero cells, they don’t answer infections within the way that standard cells would. Studying viruses with organoids remains a replacement pursuit, but many consider them an exciting model for exploring interactions between human cells and viruses, and therefore the technology could make the response to subsequent pandemics much faster.
Also read: Best Biotechnology colleges in India
One thought on “Organoid Technology helps to beat COVID-19”